Honokiol increases the expression of microRNA-188-5p, which upregulates FBXW7, a tumor suppressor gene that downregulates c-Myc, effectively reversing drug resistance and inhibiting tumor growth.44 Moreover, honokiol enhances doxorubicin’s efficacy by regulating mucin 1 and multidrug resistance protein 1, further improving its therapeutic effects and reducing the likelihood of resistance.45 Importantly, honokiol’s cardioprotective properties provide a significant advantage, offering a safer combination therapy for patients receiving doxorubicin. The gene discussed is MYC; the disease is neoplasm.